Inflammatory bowel disease (IBD), including Crohn's disease and Ulcerative colitis, often shows variable responses to biological therapies. Identifying the most significant variables for predicting the response to these therapies could help prioritiz...
The lancet. Gastroenterology & hepatology
Jul 1, 2025
BACKGROUND: Biological therapeutics are widely used in Crohn's disease, with evidence of efficacy from randomised trials and real-world experience. Primary non-response is a common, poorly understood problem. We aimed to assess blood methylation as a...
IMPORTANCE: Biological therapies have revolutionized inflammatory bowel disease management, but many patients do not respond to biological monotherapy. Identification of likely responders could reduce costs and delays in remission.
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.